GlassScriptPhysician profile
Sandra A Voss
NPI 1386664837
$2,095.36
in general payments reported to CMS, 2019-2025
17 companies · $817 in 2025
The $817 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $406 · 2023: $234 · 2024: $484 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.92 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $388.60 | 2021-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $265.27 | 2024-2025 | Calquence |
| Merck Sharp & Dohme LLC | $232.10 | 2022-2024 | Keytruda |
| Jazz Pharmaceuticals INC. | $135.32 | 2025 | |
| Sobi, INC | $125.00 | 2022 | |
| Eisai INC. | $125.00 | 2022 | |
| Astellas Pharma US INC | $125.00 | 2023 | Padcev |
| Gilead Sciences, INC. | $125.00 | 2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2025 | Libtayo |
| Abbvie INC. | $103.70 | 2025 | |
| Glaxosmithkline, LLC. | $96.38 | 2024 | Zejula |
| Mirati Therapeutics, INC. | $90.00 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $77.49 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.23 | 2025 | Fruzaqla |
| Ipsen Biopharmaceuticals, INC | $25.32 | 2024 | Onivyde |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12.52 | 2022 | |
| Pfizer INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.